Home Alzheimer’s Disease Neal D. Shore, MD, FACS Discusses Impact, Treatment Implications of the Phase...

Neal D. Shore, MD, FACS Discusses Impact, Treatment Implications of the Phase III HERO Trial

Results presented at the 2020 ASCO Virtual Scientific Program demonstrated that once daily oral relugolix (Relumina), a gonadotrophin-releasing hormone (GnRH) antagonist, induced sustained castration in 96.7% of patients with advanced prostate cancer, meeting the trial’s primary endpoint. These findings met the superiority threshold for relugolix when compared with leuprolide (Lupron).

 

In an interview with CancerNetwork, Neal D. Shore, MD, FACS of the Carolina Urologic Research Center discussed the significance of these findings and the benefits of relugolix as a GnRH antagonist.

 

Transcription:

 

So, if I could summarize how this new once daily oral GnRH antagonist medication could change the landscape of treatment for our patients with advanced prostate cancer, I would say that historically and contemporaneously, we only have a parenteral administration of testosterone (T)…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments